Objectives: A selective and novel method has been optimized for the evaluation of remogliflozin and metformin hydrochloride in bulk and in the formulation and cleaning of samples by UPLC-PDA in bulk and formulation and product traces.
Materials And Methods: The principle analytes were eluted with phosphate buffer (pH: 4.5): acetonitrile (60:40%, v/v) as the mobile phase using the Spherisorb C18, 5 μm, 4.6 mm x 150 mm analytical column with a 1.0 mL/min flow rate and a 10 μL sample volume at 245 nm in a photodiode array detector.
Results: The retention times of remogliflozin and metformin hydrochloride were 3.017 min and 5.011 min with a total run time of 8 min. The curve indicates that the correlation coefficient (r) was superior with a value of 1.000 in the linear range of 10 ng/mL-100.0 ng/mL for remogliflozin and 50 ng/mL-500.0 ng/mL for metformin hydrochloride. The correlation coefficient (r) for metformin hydrochloride was found to be 1.000. The lower limits of quantification and detection for remogliflozin and metformin hydrochloride were found to be 10 ng/mL and 50 ng/mL, and 5 ng/mL and 10 ng/mL, respectively.
Conclusion: The developed method was validated and applied to the bulk drug estimation and drug formulation and cleaning samples. All the results obtained with this method was accurate and precise.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231326 | PMC |
http://dx.doi.org/10.4274/tjps.galenos.2020.39699 | DOI Listing |
Psychol Health Med
January 2025
Faculty of Medicine Umm Al-Qura University, Al-Qunfudah, Saudi Arabia.
Patients with type 2 diabetes mellitus (T2DM) are susceptible to mental health issues, impacting medication adherence and diabetes control. This study aimed to evaluate factors associated with depression and anxiety among T2DM patients in Indonesia and Malaysia. A cross-sectional study was conducted in Indonesia and Malaysia from October 2022 to April 2023 among T2DM patients.
View Article and Find Full Text PDFPLoS One
January 2025
Department of Endocrinology and Metabolism, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.
Sodium-glucose co-transporter 2 inhibitors, such as enavogliflozin, offer promising metabolic benefits for patients with type 2 diabetes (T2D), including glycemic control and improved cardiac function. Despite the clinical evidence, real-world evidence is needed to validate their safety and effectiveness. This study aims to evaluate the effects of weight loss and safety of enavogliflozin administration in patients with T2D in a real-world clinical setting over 24 weeks.
View Article and Find Full Text PDFANZ J Surg
January 2025
Department of Surgery, Western Health, St. Albans, Victoria, Australia.
Background: Metformin is a diabetes medication with anti-mitotic properties. A narrative review was performed to investigate people using metformin and the risk of developing pancreatic ductal adenocarcinoma (PDAC) as well as survival outcomes in established PDAC.
Methods: Relevant studies on metformin use and PDAC were retrieved from PubMed including observational studies on metformin and the risk of developing PDAC and survival outcomes in PDAC, and randomized controlled trials of metformin as a treatment in PDAC.
Severe aortic valve stenosis poses a significant risk for the aging population, often escalating from mild symptoms to life-threatening heart failure and sudden death. Without timely intervention, this condition can lead to disastrous outcomes. The advent of transcatheter aortic valve implantation (TAVI) has gained popularity, emerging as an effective alternative for managing severe aortic stenosis (AS) in high-risk patients experiencing deterioration of previously implanted bioprosthetic surgical aortic valves (SAV), which introduces complex challenges such as device compatibility and anatomical considerations.
View Article and Find Full Text PDFFront Pharmacol
January 2025
School of Pharmacy, Xinjiang Medical University, Urumchi, China.
Background: In the Kazakh community of Xinjiang, China, fermented camel milk has been traditionally used to manage diabetes. This study evaluates the effects of composite probiotics derived from fermented camel milk (CPCM) on metabolic disturbances in a rat model of Type 2 diabetes (T2DM).
Methods: T2DM was induced in Wistar rats using streptozotocin.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!